Cleo Diagnostics Selects Bio-Techne's Platform as Immunoassay Instrument for Ovarian Cancer Blood Test; Shares Jump 3%

MT Newswires Live02-18

Cleo Diagnostics (ASX:COV) selected Bio-Techne's Ella enzyme-linked immunosorbent assay platform as the immunoassay instrument for its ovarian cancer blood test, according to a Wednesday Australian bourse filing.

The companies are progressing discussions to enter into a binding agreement to start analytical validation of Cleo's test kits, the filing said. Cleo has been using the Ella platform in-house since September 2025 and confirmed the platform's capability to deliver its tests.

The finished kits will then be used test the around 500 blood samples collected as part of Cleo's pivotal clinical trial, per the filing.

Cleo Diagnostics' shares jumped nearly 3% in recent trading on Wednesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2612492145?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-18 10:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612492145","market":"sh","top_or_hot":-1,"title":"Cleo Diagnostics Selects Bio-Techne's Platform as Immunoassay Instrument for Ovarian Cancer Blood Test; Shares Jump 3%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/COV.AU\">Cleo Diagnostics</a> (ASX:COV) selected Bio-Techne's Ella enzyme-linked immunosorbent assay platform as the immunoassay instrument for its ovarian cancer blood test, according to a Wednesday Australian bourse filing.</p><p>The companies are progressing discussions to enter into a binding agreement to start analytical validation of Cleo's test kits, the filing said. Cleo has been using the Ella platform in-house since September 2025 and confirmed the platform's capability to deliver its tests.</p><p>The finished kits will then be used test the around 500 blood samples collected as part of Cleo's pivotal clinical trial, per the filing.</p><p>Cleo Diagnostics' shares jumped nearly 3% in recent trading on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cleo Diagnostics Selects Bio-Techne's Platform as Immunoassay Instrument for Ovarian Cancer Blood Test; Shares Jump 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCleo Diagnostics Selects Bio-Techne's Platform as Immunoassay Instrument for Ovarian Cancer Blood Test; Shares Jump 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-18 10:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/COV.AU\">Cleo Diagnostics</a> (ASX:COV) selected Bio-Techne's Ella enzyme-linked immunosorbent assay platform as the immunoassay instrument for its ovarian cancer blood test, according to a Wednesday Australian bourse filing.</p><p>The companies are progressing discussions to enter into a binding agreement to start analytical validation of Cleo's test kits, the filing said. Cleo has been using the Ella platform in-house since September 2025 and confirmed the platform's capability to deliver its tests.</p><p>The finished kits will then be used test the around 500 blood samples collected as part of Cleo's pivotal clinical trial, per the filing.</p><p>Cleo Diagnostics' shares jumped nearly 3% in recent trading on Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TECH","symbol_name":"Techne Corporation","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2612492145","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612492145","pubTimestamp":1771380745,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cleo Diagnostics  selected Bio-Techne's Ella enzyme-linked immunosorbent assay platform as the immunoassay instrument for its ovarian cancer blood test, according to a Wednesday Australian bourse filing.The companies are progressing discussions to enter into a binding agreement to start analytical validation of Cleo's test kits, the filing said. Cleo has been using the Ella platform in-house since September 2025 and confirmed the platform's capability to deliver its tests.The finished kits will then be used test the around 500 blood samples collected as part of Cleo's pivotal clinical trial, per the filing.Cleo Diagnostics' shares jumped nearly 3% in recent trading on Wednesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TECH":"Techne Corporation","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","BK4588":"碎股","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","BK7067":"生物科技","BK4121":"生命科学工具和服务","COV.AU":"Cleo Diagnostics Ltd"},"translate_title":"Cleo Diagnostics选择Bio-Techne的平台作为卵巢癌血液检测的免疫测定仪器；股价上涨3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TECH":1.5,"COV.AU":1},"content_text":"Cleo Diagnostics (ASX:COV) selected Bio-Techne's Ella enzyme-linked immunosorbent assay platform as the immunoassay instrument for its ovarian cancer blood test, according to a Wednesday Australian bourse filing.The companies are progressing discussions to enter into a binding agreement to start analytical validation of Cleo's test kits, the filing said. Cleo has been using the Ella platform in-house since September 2025 and confirmed the platform's capability to deliver its tests.The finished kits will then be used test the around 500 blood samples collected as part of Cleo's pivotal clinical trial, per the filing.Cleo Diagnostics' shares jumped nearly 3% in recent trading on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2612492145","isCrawlerRequest":true}